Literature DB >> 22923696

Inhibitory signaling through signal regulatory protein-α is not sufficient to explain the antitumor activities of CD47 antibodies.

David R Soto-Pantoja, Thomas W Miller, William A Frazier, David D Roberts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22923696      PMCID： PMC3479493          DOI： 10.1073/pnas.1205441109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  5 in total

1.  CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.

Authors:  Xi Wen Zhao; Ellen M van Beek; Karin Schornagel; Hans Van der Maaden; Michel Van Houdt; Marielle A Otten; Pascal Finetti; Marjolein Van Egmond; Takashi Matozaki; Georg Kraal; Daniel Birnbaum; Andrea van Elsas; Taco W Kuijpers; Francois Bertucci; Timo K van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

2.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

3.  CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation.

Authors:  X Han; H Sterling; Y Chen; C Saginario; E J Brown; W A Frazier; F P Lindberg; A Vignery
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

4.  Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling.

Authors:  Justin B Maxhimer; David R Soto-Pantoja; Lisa A Ridnour; Hubert B Shih; William G Degraff; Maria Tsokos; David A Wink; Jeff S Isenberg; David D Roberts
Journal:  Sci Transl Med       Date:  2009-10-21       Impact factor: 17.956

5.  CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis.

Authors:  P A Oldenborg; H D Gresham; F P Lindberg
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307
  5 in total
  14 in total

1.  On the mechanism and benefit of siRNA-mediated targeting of CD47 in cancer.

Authors:  Xiwen Zhao; Hanke Matlung; Taco W Kuijpers; Timo K van den Berg
Journal:  Mol Ther       Date:  2013-10       Impact factor: 11.454

Review 2.  Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific 'Marker of Self' CD47, and target physical properties.

Authors:  Nisha G Sosale; Kyle R Spinler; Cory Alvey; Dennis E Discher
Journal:  Curr Opin Immunol       Date:  2015-07-13       Impact factor: 7.486

3.  Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer.

Authors:  David D Roberts; Sukhbir Kaur; David R Soto-Pantoja
Journal:  J Cell Commun Signal       Date:  2015-03-18       Impact factor: 5.782

Review 4.  Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.

Authors:  David R Soto-Pantoja; Erica V Stein; Natasha M Rogers; Maryam Sharifi-Sanjani; Jeffrey S Isenberg; David D Roberts
Journal:  Expert Opin Ther Targets       Date:  2012-10-27       Impact factor: 6.902

5.  Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment.

Authors:  Sukhbir Kaur; Kyle V Cicalese; Rajdeep Bannerjee; David D Roberts
Journal:  Antib Ther       Date:  2020-08-08

6.  Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.

Authors:  Anthony L Schwartz; Pulak R Nath; Michael Allgauer; Elizabeth C Lessey-Morillon; John M Sipes; Lisa A Ridnour; Y Maurice Morillon Ii; Zhiya Yu; Nicholas P Restifo; David D Roberts
Journal:  Cancer Immunol Immunother       Date:  2019-10-18       Impact factor: 6.968

Review 7.  Functions of Thrombospondin-1 in the Tumor Microenvironment.

Authors:  Sukhbir Kaur; Steven M Bronson; Dipasmita Pal-Nath; Thomas W Miller; David R Soto-Pantoja; David D Roberts
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 6.208

Review 8.  Insights into CD47/SIRPα axis-targeting tumor immunotherapy.

Authors:  Xuyao Zhang; Jiajun Fan; Dianwen Ju
Journal:  Antib Ther       Date:  2018-08-28

9.  Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.

Authors:  Jie Liu; Lijuan Wang; Feifei Zhao; Serena Tseng; Cyndhavi Narayanan; Lei Shura; Stephen Willingham; Maureen Howard; Susan Prohaska; Jens Volkmer; Mark Chao; Irving L Weissman; Ravindra Majeti
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

10.  Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors.

Authors:  Sukhbir Kaur; David R Soto-Pantoja; Erica V Stein; Chengyu Liu; Abdel G Elkahloun; Michael L Pendrak; Alina Nicolae; Satya P Singh; Zuqin Nie; David Levens; Jeffrey S Isenberg; David D Roberts
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.